BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Yuasa A, Yonemoto N, LoPresti M, Ikeda S. Productivity loss/gain in cost-effectiveness analyses for vaccines: a systematic review. Expert Rev Pharmacoecon Outcomes Res 2021;21:235-45. [PMID: 33593223 DOI: 10.1080/14737167.2021.1881484] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
Number Citing Articles
1 Jiang S, Wang Y, Si L, Zang X, Gu YY, Jiang Y, Liu GG, Wu J. Incorporating productivity loss in health economic evaluations: a review of guidelines and practices worldwide for research agenda in China. BMJ Glob Health 2022;7:e009777. [PMID: 35977755 DOI: 10.1136/bmjgh-2022-009777] [Reference Citation Analysis]
2 Beck E, Biundo E, Devlin N, Doherty TM, Garcia-Ruiz AJ, Postma M, Sheikh S, Smela B, Toumi M, Wasem J, Nolan T, Salisbury D. Capturing the value of vaccination within health technology assessment and health economics: Literature review and novel conceptual framework. Vaccine 2022;40:4008-16. [PMID: 35618559 DOI: 10.1016/j.vaccine.2022.04.050] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
3 Rasmussen MK, Kronborg C, Fasterholdt I, Kidholm K. Economic evaluations of interventions against viral pandemics: a scoping review. Public Health 2022;208:72-9. [PMID: 35724446 DOI: 10.1016/j.puhe.2022.05.001] [Reference Citation Analysis]
4 Kohli MA, Maschio M, Mould-Quevedo JF, Ashraf M, Drummond MF, Weinstein MC. The Cost-Effectiveness of Expanding Vaccination with a Cell-Based Influenza Vaccine to Low Risk Adults Aged 50 to 64 Years in the United Kingdom. Vaccines (Basel) 2021;9:598. [PMID: 34199912 DOI: 10.3390/vaccines9060598] [Cited by in F6Publishing: 4] [Reference Citation Analysis]